Enliven Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update Reported positive initial Phase 1 b data for ELVN-001 in CML. Strong balance sheet with $463 million in cash, cash equivalents and marketable securities, which is expected to provide cash runway into the first half of 2029. BOULDER, Colo., March 3, 2026/ PRNewswire/-- Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the discovery...

#ELVN Enliven Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update

www.stocktitan.net/news/ELVN/enliven-therap...

#ELVN Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update

www.stocktitan.net/news/ELVN/enliven-therap...

Enliven Therapeutics Announces Clinical Data in CML Patients with Atypical Fusion Transcripts at ASH 2025 Annual Meeting ELVN-001 demonstrates encouraging anti-CML activity in heavily pretreated patients with atypical fusion transcripts. Growing unmet need for patients with atypical transcript e13a3, which is resistant to TKIs targeting the myristoyl pocket. BOULDER, Colo., Nov. 3, 2025/ PRNewswire/-- Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company...

#ELVN Enliven Therapeutics Announces Clinical Data in CML Patients with Atypical Fusion Transcripts at ASH 2025 Annual Meeting

www.stocktitan.net/news/ELVN/enliven-therap...

Trade Alerts, Tuesday September 9, 2025 – Crystal Equity Research

Small-cap stocks registering bearish MACD Crossover, Tue Sept 9th - #OVID #NAAS #MBWM #LE #KE #INUA #GABC #FLYW #ELVN #CLMB #SCSC #BRLT #ALGT #WGO #USNA #SHO #TUYA - More: crystalequityresearch.com/trade-alerts... - #smallcap

Clinical-Stage Biotech Enliven to Present Novel BCR::ABL1 Inhibitor Data for Chronic Myeloid Leukemia Enliven Therapeutics will present Phase 1a/1b ENABLE trial data for ELVN-001, a selective BCR::ABL1 inhibitor, in previously treated CML patients at SOHO 2025 Annual Meeting in Houston.

#ELVN Enliven Therapeutics Announces Oral and Poster Presentations at the Society of Hematologic Oncology (SOHO) 2025 Annual Meeting

www.stocktitan.net/news/ELVN/enliven-therap...

Enliven's Leukemia Drug Outperforms Competitors in Phase 1 Trial, Backed by $491M Cash Reserve Novel CML treatment ELVN-001 achieves 32% MMR rate by week 24, surpassing existing therapies. Biotech maintains strong cash position through 2029. See full results.

#ELVN Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update

www.stocktitan.net/news/ELVN/enliven-therap...

Enliven Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants Enliven Therapeutics (ELVN) has announced the pricing of its public offering, consisting of 8,394,737 shares of common stock at $19.66 per share and pre-funded warrants for up to 1,780,263 shares at $19.659 per warrant. The gross proceeds are expected to be approximately $200 million before deducting expenses. The offering is set to close around June 16, 2025. The company has granted underwriters a 30-day option to purchase up to an additional 1,526,250 shares. Jefferies, Goldman Sachs & Co. LLC, TD Cowen, and Mizuho are serving as joint book-running managers, with LifeSci Capital acting as lead manager for the offering.

#ELVN Enliven Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

www.stocktitan.net/news/ELVN/enliven-therap...

Enliven Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants Enliven Therapeutics (Nasdaq: ELVN), a clinical-stage biopharmaceutical company, has announced a proposed public offering of $200 million in common stock and pre-funded warrants. The company will also grant underwriters a 30-day option to purchase up to an additional $30 million in common stock. The offering is being managed by joint book-runners Jefferies, Goldman Sachs & Co. LLC, TD Cowen, and Mizuho, with LifeSci Capital as lead manager. The offering will be made through a Registration Statement on Form S-3 and is subject to market conditions and regulatory approval.

#ELVN Enliven Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

www.stocktitan.net/news/ELVN/enliven-therap...

Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML at EHA 2025 Congress Enliven Therapeutics (NASDAQ: ELVN) reported positive Phase 1 data for ELVN-001 in chronic myeloid leukemia (CML) at EHA 2025. The trial showed a 47% cumulative MMR rate by 24 weeks, with 32% achieving and 100% maintaining MMR. Among 90 enrolled patients with median treatment of 29 weeks, 67% received three or more prior TKIs. ELVN-001 demonstrated favorable safety with only 3.4% dose reductions and 4.6% discontinuations due to adverse events. The drug showed promising efficacy in heavily pretreated patients, including those resistant to prior therapies, with MMR rates comparing favorably to historical data. The pharmacokinetic profile supports once-daily dosing, and no maximum tolerated dose was reached. Enliven plans to initiate a head-to-head Phase 3 pivotal trial in 2026.

#ELVN Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML at EHA 2025 Congress

www.stocktitan.net/news/ELVN/enliven-therap...

Enliven Reports Breakthrough: 44% Response Rate in CML Drug Trial Surpasses Expectations New Phase 1 data reveals ELVN-001's strong efficacy in CML patients with 82% retention rate. Plus Q1 financials show $290M cash runway. See full results.

#ELVN Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update

www.stocktitan.net/news/ELVN/enliven-therap...

Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML and Oral Presentation at the EHA 2025 Congress Enliven Therapeutics (NASDAQ: ELVN) reported updated positive data from its Phase 1 ENABLE clinical trial of ELVN-001 in chronic myeloid leukemia (CML) patients. Key highlights include: The trial showed a 44% cumulative major molecular response (MMR) rate (16 of 36 patients) by 24 weeks, with 26% achieving and 100% maintaining MMR. The study enrolled 74 heavily pretreated patients, with 66% having received three or more prior tyrosine kinase inhibitors (TKIs). ELVN-001, a selective BCR::ABL1 kinase inhibitor, demonstrated strong efficacy in resistant cases, with 40% of TKI-resistant patients achieving MMR. The drug showed a favorable safety profile across all doses, with low rates of dose interruptions (

#ELVN Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML and Oral Presentation at the EHA 2025 Congress

www.stocktitan.net/news/ELVN/enliven-therap...

Major Cancer Drug Breakthrough: Enliven Unveils Triple-Asset Data at AACR 2025 New data reveals breakthrough potential of three cancer therapeutics targeting HER2, RAF, and ABL1. Key findings on resistance mechanisms and combination approaches. Full analysis inside.

#ELVN Enliven Therapeutics Announces Poster Presentations at the 2025 AACR Annual Meeting

www.stocktitan.net/news/ELVN/enliven-therap...

Enliven Therapeutics Secures 3-Year Runway with $313M War Chest, Advances Cancer Drug Pipeline Enliven maintains robust $313.4M cash position through 2027, advancing CML drug ELVN-001 toward pivotal trial while expanding ELVN-002 studies for HER2+ cancers.

#ELVN Enliven Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

www.stocktitan.net/news/ELVN/enliven-therap...

#ELVN Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update

www.stocktitan.net/news/ELVN/enliven-therap...